DiBiCol Diagnostic

Challenges in diagnosing IBD

Approximately three million people in the EU and U.S. suffer from inflammatory bowel disease. The traditional methods used to discriminate between ulcerative colitis and Crohn’s disease are sufficient, why 10-15 % of the patients never get a complete diagnosis.  These patients are said to have an unclassified form; Inflammatory Bowel Disease Unclassified (IBDU). In some cases, a previously established diagnosis is changed during the disease history of a patient. To not be able to set a diagnosis is unfortunate since treatment and surgery may differ between the diseases. Furthermore, there is additional stress for the patient not knowing what disease he or she has.


DiBiCol is a diagnostic method to differentiate between ulcerative colitis and Crohn’s disease, the two major forms of inflammatory bowel disease (IBD). At the same time the test either confirms (IBD), or points to other non-IBD conditions like the less severe condition Irritable Bowel Syndrome (IBS).

A unique method to classify IBD

DiBiCol is a PCR-based method that monitors seven proprietary biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. By applying a specially designed algorithm a diagnosis can be made. DiBiCol provides objective test results, and allows treating physicians to prescribe the most appropriate treatment options on an individual patient basis.

Verified in clinical studies and routine clinical use

DiBiCol has been verified in three clinical studies including more than 300 patients and the results were published in Gastroenterology, June 2008. In 2009, DiBiCol was introduced on the Swedish market and has since been used in clinical routine practice at a number of clinics, as reported in European Gastroenterology & Hepatology Review, Spring 2012. The performance of DiBiCol was confirmed in a study conducted by Janczewska et al. Scandinavian Journal of Gastroenterology, February 2012, click here for abstract.